TMCnet News
Trimel to Report Financial Results for 2014 and Host Conference Call to Update InvestorsTrimel Pharmaceuticals Corporation (TSX:TRL) will report its financial results for the three and twelve month periods ended December 31, 2014 on Thursday, March 5, 2015. Management of the Company will host a conference call to discuss these results and provide an update to investors on Friday, March 6, 2015 at 8:30 a.m. Eastern Time. Following the discussion, Trimel executives will address inquiries from investment analysts. To access the call live, please dial 416-340-8527 or 1-800-355-4959. Listeners are encouraged to dial in 10 minutes before the call begins to avoid delays. A replay of the conference call will be available until 7:00 p.m. Eatern Time on Friday, March 13, 2015 by dialing 905-694-9451 or 1-800-408-3053, using access code: 9028061#. About Trimel Trimel is a specialty pharmaceutical company involved in the sale, distribution and development of products with a focus in men's and women's health. Trimel markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing Trimel's licensed nasal gel technology, is the first testosterone nasal gel filed in Canada for approval, and is the first and only approved testosterone nasal gel in the United States for replacement therapy in adult males diagnosed with hypogonadism. The commercial rights to NATESTO™ in the United States and Mexico have been licensed by Trimel to an affiliate of Endo International plc. For more information, please visit www.trimelpharmaceuticals.com.
|
